Current Value
$159.071 Year Return
Current Value
$159.071 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VGIT | -0.14% | $31.83B | 0.04% |
WIP | -0.31% | $379.93M | 0.5% |
BOXX | 0.37% | $6.97B | 0.19% |
MEAR | -0.39% | $1.14B | 0.25% |
SGOV | 0.45% | $50.94B | 0.09% |
IBTL | -0.51% | $386.59M | 0.07% |
WEAT | 0.54% | $124.92M | 0.28% |
BNDX | 0.64% | $67.48B | 0.07% |
IBTF | -0.67% | $1.98B | 0.07% |
RING | -0.77% | $1.44B | 0.39% |
STXT | 0.78% | $128.89M | 0.49% |
MLN | 0.78% | $513.44M | 0.24% |
GDXJ | 1.03% | $5.48B | 0.51% |
SHV | 1.14% | $20.75B | 0.15% |
IBTM | 1.22% | $317.86M | 0.07% |
CANE | -1.30% | $11.17M | 0.29% |
SCHR | 1.47% | $10.87B | 0.03% |
FLMI | -1.48% | $745.34M | 0.3% |
SHY | -1.56% | $23.69B | 0.15% |
SPTI | 1.64% | $8.68B | 0.03% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -16.27% | $24.71B | +36.77% | 1.07% |
CME | -13.48% | $99.84B | +44.13% | 1.75% |
PHYS.U | -12.27% | - | - | 0.00% |
VSTA | -8.80% | $325.62M | +40.00% | 0.00% |
ZCMD | -8.59% | $28.79M | -11.91% | 0.00% |
SAND | -8.30% | $2.88B | +71.80% | 0.59% |
GFI | -8.25% | $21.69B | +51.82% | 2.28% |
DFDV | -7.81% | $361.15M | +2,667.20% | 0.00% |
MVO | -7.61% | $69.92M | -35.18% | 21.79% |
OR | -7.50% | $5.15B | +57.13% | 0.71% |
LNTH | -7.27% | $5.75B | -32.58% | 0.00% |
AU | -7.01% | $24.15B | +65.64% | 2.14% |
AWK | -7.00% | $27.95B | +5.15% | 2.18% |
AEM | -6.84% | $60.44B | +59.95% | 1.35% |
CEF | -6.80% | - | - | 0.00% |
PM | -6.69% | $281.34B | +72.03% | 3.00% |
STG | -5.76% | $56.15M | +27.66% | 0.00% |
DRD | -5.76% | $1.18B | +42.77% | 2.05% |
MKTX | -5.60% | $8.15B | -1.09% | 1.39% |
EXC | -5.59% | $43.84B | +22.86% | 3.60% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPH | 63.68% | $728.37M | 0.4% |
FXH | 63.21% | $891.10M | 0.62% |
IBB | 62.58% | $5.59B | 0.45% |
BBH | 62.06% | $345.62M | 0.35% |
SMOT | 61.44% | $403.05M | 0.49% |
MOAT | 61.35% | $12.98B | 0.47% |
EZM | 61.31% | $794.95M | 0.38% |
PBE | 60.86% | $233.59M | 0.58% |
SIZE | 60.81% | $353.98M | 0.15% |
IJS | 60.76% | $6.38B | 0.18% |
COWZ | 60.57% | $20.98B | 0.49% |
DFSV | 60.19% | $4.99B | 0.3% |
VIOV | 60.00% | $1.33B | 0.1% |
IVOV | 59.89% | $965.50M | 0.1% |
CALF | 59.86% | $4.28B | 0.59% |
MDYV | 59.84% | $2.48B | 0.15% |
EES | 59.70% | $612.84M | 0.38% |
IJJ | 59.66% | $7.97B | 0.18% |
SLYV | 59.58% | $3.85B | 0.15% |
VIOO | 59.57% | $2.94B | 0.1% |
Double maintains 5 strategies that include CRL - Charles River Laboratories International, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -44.02% | $94.90M | 0.59% |
VIXY | -43.82% | $200.94M | 0.85% |
VIXM | -43.65% | $22.99M | 0.85% |
BTAL | -40.68% | $310.24M | 1.43% |
IVOL | -33.94% | $341.06M | 1.02% |
FXY | -23.94% | $798.58M | 0.4% |
FXE | -23.45% | $592.85M | 0.4% |
UDN | -21.81% | $147.26M | 0.78% |
CLIP | -20.26% | $1.51B | 0.07% |
SHYM | -20.01% | $355.87M | 0.35% |
BWX | -19.30% | $1.53B | 0.35% |
FTSD | -18.45% | $233.24M | 0.25% |
ULST | -15.29% | $592.71M | 0.2% |
SPTS | -14.62% | $5.78B | 0.03% |
XONE | -14.28% | $629.16M | 0.03% |
IBND | -13.71% | $407.57M | 0.5% |
XHLF | -13.24% | $1.73B | 0.03% |
IGOV | -12.42% | $1.25B | 0.35% |
IBTG | -12.10% | $1.93B | 0.07% |
BILS | -12.06% | $3.80B | 0.1356% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IQV | 74.56% | $27.70B | -29.11% | 0.00% |
TECH | 63.48% | $8.25B | -31.85% | 0.61% |
RVTY | 62.73% | $11.61B | -8.92% | 0.29% |
TRMB | 60.69% | $19.13B | +39.99% | 0.00% |
MEDP | 60.05% | $9.21B | -27.92% | 0.00% |
CDW | 59.41% | $23.40B | -23.66% | 1.40% |
A | 59.18% | $34.11B | -8.34% | 0.84% |
KE | 58.47% | $477.12M | -14.62% | 0.00% |
DIS | 57.77% | $215.68B | +23.85% | 0.84% |
SLAB | 57.71% | $4.56B | +14.32% | 0.00% |
IPGP | 57.23% | $3.16B | -16.97% | 0.00% |
MTD | 57.11% | $24.81B | -12.12% | 0.00% |
AZTA | 56.28% | $1.48B | -39.63% | 0.00% |
POWI | 56.23% | $3.19B | -24.92% | 1.45% |
ROG | 56.05% | $1.26B | -47.11% | 0.00% |
ADI | 56.00% | $120.82B | +2.41% | 1.56% |
EMR | 55.61% | $78.69B | +19.60% | 1.50% |
BRKR | 55.52% | $6.55B | -31.86% | 0.46% |
TXN | 55.46% | $199.91B | +9.07% | 2.44% |
HLIO | 55.43% | $1.15B | -24.62% | 1.03% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FNV | 0.01% | $30.53B | +24.50% | 0.94% |
AEP | 0.03% | $56.10B | +15.48% | 3.51% |
PG | 0.03% | $360.50B | -6.57% | 2.66% |
WBX | 0.10% | $84.88M | -79.58% | 0.00% |
EQX | -0.18% | $4.77B | +5.89% | 0.00% |
KO | -0.19% | $299.02B | +9.56% | 2.87% |
EZPW | 0.22% | $781.20M | +40.18% | 0.00% |
ALHC | -0.30% | $2.65B | +49.22% | 0.00% |
VSA | 0.33% | $12.16M | +21.20% | 0.00% |
LTM | -0.36% | $12.57B | -95.57% | 2.41% |
KR | -0.51% | $47.78B | +38.66% | 1.78% |
VHC | -0.58% | $74.47M | +193.32% | 0.00% |
BTI | -0.65% | $112.32B | +59.44% | 5.94% |
KROS | 0.72% | $591.77M | -71.45% | 0.00% |
RGLD | -0.83% | $10.52B | +16.83% | 1.11% |
BTCT | -0.89% | $29.39M | +101.55% | 0.00% |
TH | -0.97% | $780.01M | -14.58% | 0.00% |
CNK | 1.18% | $3.43B | +40.21% | 0.54% |
KGC | 1.18% | $19.13B | +70.94% | 0.77% |
NEUE | -1.20% | $60.89M | +31.91% | 0.00% |
Finnhub
Charles River Laboratories International, Inc. will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled to discuss...
Yahoo
A number of stocks fell in the morning session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
Finnhub
Myrtelle Inc. announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus gene therapy product, developed specifically for...
Yahoo
Myrtelle Inc. ("Myrtelle" or the "Company"), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, today announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus (rAAV) gene therapy product, developed specifically for Canavan disease (CD). This landmark achievement propels Myrtelle's therapy closer to market and patients who urgently need it.
Yahoo
Charles River Laboratories’ first quarter drew a highly positive market response, with results driven by stronger-than-expected demand in its Drug Safety Assessment (DSA) segment and signs of stabilization across client groups. Management credited improved bookings and a net book-to-bill ratio above 1x for the DSA segment, noting this was the first such result in over two years. CEO Jim Foster highlighted, “We were pleased to see the DSA net book-to-bill return to just above 1x for the first tim
SeekingAlpha
FDA's plan to phase out animal testing may hurt Charles River's revenues. The DCF model suggests that CRL presents an overvaluation of 29.68%. See more.